SCHEMBL6035628

SCHEMBL6035628

CC(C)c1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1nn(C)cc1CCC(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 3/20 0.37
GCG P01275 3/20 0.34
PANK3 Q9H999 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
HDAC4 P56524 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
HPGD P15428 1/20 0.33
TIPARP Q7Z3E1 1/20 0.33
MLYCD O95822 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
KDM4E B2RXH2 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
SCN9A Q15858 1/20 0.32
LMNA P02545 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
ACACB O00763 1/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632906 0.92 GCGR (0.34) GCGRGCGPANK3SMN1; SMN2HDAC4
SCHEMBL6034614 0.87 GCGR (0.39) GCGRGCGSMN1; SMN2HDAC4HPGD
SCHEMBL6253122 0.85 PANK3 (0.35) GCGRPANK3SMN1; SMN2HDAC4HRH3
SCHEMBL6036397 0.84 GCGR (0.36) GCGRGCGSMN1; SMN2HDAC4HRH3
SCHEMBL6036015 0.83 GCGR (0.35) GCGRGCGPANK3SMN1; SMN2HDAC4
SCHEMBL6034481 0.82 FFAR1 (0.43) GCGRGCGL3MBTL1LMNAPPARG
SCHEMBL6034968 0.82 HCRTR1 (0.38) GCGRSMN1; SMN2HCRTR1HCRTR2KDM4E
SCHEMBL6035903 0.82 SMN1; SMN2 (0.41) GCGRSMN1; SMN2HDAC4HPGDHCRTR1
SCHEMBL6035517 0.82 FFAR4 (0.38) GCGRSMN1; SMN2KDM4EPPARG
SCHEMBL6036403 0.81 GCGR (0.36) GCGRGCGSMN1; SMN2HDAC4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 GCGR 93/4885GCG 284/4885PANK3 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.